Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

7(70.0%)

Phase 2

2(20.0%)

N/A

1(10.0%)

10Total

Phase 1(7)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06704009Phase 1Active Not Recruiting

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

Role: collaborator

NCT03743623Not ApplicableCompleted

Neurocytotron on Cerebral Palsy

Role: collaborator

NCT04505839Phase 1Completed

First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Role: collaborator

NCT04795037Phase 1Completed

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Role: collaborator

NCT03800420Phase 2Terminated

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Role: collaborator

NCT02674399Phase 2Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

Role: collaborator

NCT03482648Phase 1Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Role: collaborator

NCT04138836Phase 1Completed

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

Role: collaborator

NCT04138849Phase 1Completed

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

Role: collaborator

NCT03830125Phase 1Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Role: collaborator

All 10 trials loaded